Circulating antibodies to guanosine in systemic lupus erythematosus: correlation with nephritis and polyserositis by acute and longitudinal analyses

Abstract

Systemic lupus erythematosus (SLE) is characterized by autoantibodies, including antibodies to the nucleosides of DNA. Guanosine is the most immunogenic nucleoside. In this study serum antiguanosine antibody levels were compared with disease activity, determined by their SLEDI score, in 86 patients with SLE. Sera from these patients were tested, by ELISA, for autoantibodies to guanosine, single-stranded DNA (ssDNA), and double-stranded DNA (dsDNA). Anti-doublestranded DNA levels were also measured by RIA. Resultant values from these assays were correlated with SLE disease activity, and compared with specific features of SLE. The strongest correlation was higher levels of antiguanosine antibodies in patients with active lupus nephritis and polyserositis compared to patients with inactive disease (P < 0.0001). Antiguanosine levels also correlated with arthritis (P < 0.006), CNS lupus (P < 0.005), and hematologic manifestations of SLE (P < 0.002). To test the validity of this association in chronic SLE, serum antiguanosine antibodies were measured in patients with SLE at various phases of disease activity. Twelve patients with SLE had serum samples drawn at active, active-improved, and inactive phases over a 3–7 y period. Differences were significant for serum antiguanosine antibodies in the active group compared to the inactive group (P < 0.05) and the active vs the active-improved group (P < 0.02), unlike those for dsDNA and ssDNA by ELISA or RIA. Antiguanosine antibodies correlated more closely with disease activity in SLE patients in this longitudinal study than either anti-dsDNA or ssDNA antibodies. Thus, antibodies to guanosine correlated as well or better with disease activity than the other anti-DNA antibodies measured and should be considered to contribute to the pathology of SLE, especially lupus nephritis.

Keywords

systemic lupus erythematosus (SLE)antinuclear antibodies autoantibodies antiguanosine

Get full access to this article

View all access options for this article.

References

Alarcon-Segovia D , Fishbein E , Estrada-Parra S . The heterogenecity of anti-DNA antibodies in systemic lupus erythematosus and other diseases . J Rheumatol 1975; 2: 172–177 .

Morimoto C , Steinberg AD , Schlossman SF , Borel Y . In vitro nucleoside specific immune response by lymphocytes from systemic lupus erythematosus . J Clin Invest 1983; 71: 1402–1409 .

Weisbart RH , Garrett RA , Liebling MR , Barnett EV , Paulus HE , Katz DH . Specificity of anti-nucleoside antibodies in systemic lupus erythematosus . Clin Immunol Immunopathol 1983; 27: 403–411 .

Erlanger BF , Sentizer D , Miller OJ , Beiser SM . Nucleic acid-reactive antibodies specific for nucleosides and nucleotides . Proceedings of Karolinska Symposium on Research Methods in Reproductive Endocrinology 29–31 May, 1972, pp 206–221 .

Humayun MZ , Jacob TM . Specificity of anti-nucleoside antibodies . Biochem J 1974; 141: 313–315 .

Stollar BD , Borel Y . Nucleoside specificity in the carrier IgG-dependent induction of tolerance . J Immunol 1976; 117: 1308–1313 .

Stollar BD . The experimental induction of antibodies to nucleic acids . Meth Enzymol 1980; 70: 71–85 .

Weisbart RH , Yee WS , Colburn KK , Whang SH , Heng MK , Boucek R . Antiguanosine antibodies: a new marker for procainamide-induced systemic lupus erythematosus . Ann Intern Med 1986; 104: 310–313 .

Totoritis MC , Tan EM , McNally EM , Rubin RL . Association of antibody to histone complex H2A-H2B with symptomatic procainamide-induced lupus . New Engl J Med 1988; 318: 1431–1436 .

10.

Colburn KK , Boucek RJ , Gusewitch G , Wong AL . B-adrenergic receptor stimulation increases anti-DNA antibody production in MRL=1 pr mice . J Rheumatol 1990; 17: 138–141 .

11.

Ohnishi K , Ebling FM , Mitchell B , Singh PR , Hahn BN , Tsao BP . Comparison of pathogenic and non-pathogenic murine antibodies to DNA: antigen binding and structural characteristics . Int Immunol 1994; 6: 817–830 .

12.

Bernstein KA , Kahl LE , Balow JE , Lefkowith JB . Serologic markers of lupus nephritis in patients: use of a tissue-based ELISA and evidence for immunopathogenic heterogeneity . Clin Exp Immunol 1994; 98: 60–65 .

13.

Foster MH , Cizman B , Madaio MP . Biology of disease. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins . Lab Invest 1993; 69: 494–507 .

14.

Krishnan C , Kaplan MH . Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of g-globulin from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis . J Clin Invest 1967; 46: 569–579 .

15.

Weisbart RH , Noritake DT , Wong AL , Chan G , Kacena A , Colburn KK . A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus . J Immunol 1990; 144: 2653–2658 .

16.

Schur PH , Sandson J . Immunologic factors and clinical activity in lupus erythematosus . New Engl J Med 1968; 278: 533–538 .

17.

Zack DJ , Stempniak M , Wong AK , Taylor C , Weisbart RH . Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody . J Immunol 1996; 157: 1082–1088 .

18.

Weisbart RH , Stempniak M , Harris S , Zack DJ , Ferreri K . An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications . J Autoimmun 1998; 11: 539-546 .

19.

Weisbart RH , Colburn KK . Effect of corticosteroids on serum autoantibodies in man . J Immunol Pharmac 1984; 8: 97–101 .

20.

Colburn KK , Gusewitch GA , Pooprasert S , Weisbart RH . Apheresis enhances the selective removal of anti-DNA antibodies in SLE . Clin Rheumatol 1990; 9: 475–482 .

21.

Tan EM , Cohen AS , Fries JF , Masi AT , McShane DJ , Rothfield NF , Schaller JG , Talal N , Winchester RJ . The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

22.

Isenberg DA , Dudeney C , Williams W et al. Measurement of anti-DNA antibodies: a reappraisal using five different methods . Ann Rheumat Dis 1987; 46: 448–456 .

23.

Gawryl MS , Chudwin DS , Langlois PF , Lint TF . The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus . Arthritis Rheum 1988; 31: 188–195 .

24.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH , and the Committee on Prognosis Studies in SLE . Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

25.

Erlanger BF , Beiser SM . Antibodies specific for ribonucleosides and ribonucleotides and their reaction with DNA . Proc Natl Acad Sci USA 1964; 52: 68–74 .

26.

Gripenberg M , Linder E , Kurki P , Engvall E . A solid phase enzymelinked immunosorbent assay (ELISA) for the demonstration of antibodies against denatured, single-stranded DNA in patient sera . Scand J Immunol 1978; 7: 151–157 .

27.

Fish F , Ziff M . A sensitive solid phase microradioimmunoassay for anti-double-stranded DNA antibodies . Arthritis Rheum 1981; 24: 534-543 .

28.

Eaton RB , Schneider G , Schur PH . Enzyme immunoassay for antibodies to native DNA . Arthritis Rheum 1983; 26: 52–62 .